Alleh Lindquist is the CEO and co-founder of FloraWorks, a cannabinoid innovation company focused on bringing science-backed minor cannabinoids into the mainstream.
As a leading supplier of hemp-derived cannabinoids to manufacturers, FloraWorks has been at the forefront of CBN research and commercialization, including helping popularize CBN as an ingredient for sleep products.
Today, the company's biggest focus is charting a regulatory pathway for CBN as a dietary supplement. After spending four years developing the safety data needed for FDA review, FloraWorks recently published peer-reviewed research supporting CBN's safety and has self-affirmed it as Generally Recognized As Safe (GRAS), with plans to submit its GRAS notification to the FDA.
As cannabis rescheduling continues to evolve, so does the opportunity to develop cannabis-based supplements and medicines. In this episode,
Alleh explains why scientific validation is essential, what it takes to navigate the FDA pathway, and how CBN could become one of the first cannabinoids to bridge the gap between the cannabis industry and mainstream consumer health products.
https://flora-works.com
https://www.linkedin.com/in/allehlindquist